German Clinical Trials Register

German Clinical Trials Register
Name	German Clinical Trials Register
Native name	Deutsches Register Klinischer Studien
Type	Clinical trial registry
Established	2007
Headquarters	Berlin
Country	Germany

German Clinical Trials Register

The German Clinical Trials Register operates as a national platform for registration of clinical studies conducted in Germany, aiming to enhance transparency in human subject research and align national practice with international initiatives. It serves investigators at institutions such as Charité – Universitätsmedizin Berlin, University Hospital Heidelberg, Universitätsklinikum Hamburg-Eppendorf, and sponsors including Bayer AG, Boehringer Ingelheim, and academic groups. The registry interoperates with global infrastructures exemplified by World Health Organization, International Committee of Medical Journal Editors, European Medicines Agency, and ClinicalTrials.gov.

Overview

The registry captures trial metadata for interventional and observational studies involving investigational products, devices, and behavioral interventions at sites such as Max Planck Institute for Multidisciplinary Sciences, Helmholtz Association, Fraunhofer Society, and regional university hospitals. It implements data standards referenced by organizations like International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, European Union Clinical Trials Regulation (EU No 536/2014), and aligns with the WHO Trial Registration Data Set to support systematic reviews by groups including Cochrane and guideline panels from institutions like Robert Koch Institute.

History and Development

Conceived in the context of reforms after debates involving Nuremberg Code legacies and regulatory modernization influenced by cases such as the DES (diethylstilbestrol) controversy and drug-safety reviews by Paul Ehrlich Institute, the registry launched in 2007 to provide a German-language portal complementary to international registers. Its evolution reflects policy shifts from the European Clinical Trials Directive 2001/20/EC through to the EU Clinical Trials Regulation implementation and responses to transparency campaigns by advocates linked to AllTrials and investigations by media outlets such as Der Spiegel and Süddeutsche Zeitung. Institutional partners included Federal Ministry of Health (Germany), Federal Institute for Drugs and Medical Devices (BfArM), and academic consortia from LMU Munich and Technical University of Munich.

Registration Process and Data Elements

Researchers—principal investigators affiliated with centers like University of Freiburg Medical Centre and trial sponsors such as Roche—submit protocol-level data including titles, objectives, eligibility criteria, interventions, outcomes, recruitment status, and timelines. Required fields reflect WHO-recommended items and elements used by registries like ISRCTN Registry and ANZCTR: trial identification numbers, funding sources (e.g., German Research Foundation (DFG), European Commission grants), ethical approval details referencing committees such as those at Charité – Universitätsmedizin Berlin Ethics Committee and safety monitoring arrangements like Data Safety Monitoring Board. Results reporting fields accommodate summary results akin to those posted on ClinicalTrials.gov and synopsis formats used by regulatory agencies including European Commission portals.

Governance, Standards, and Compliance

Governance involves stakeholders from academic institutions, regulatory authorities such as BfArM and Paul Ehrlich Institute, and professional societies including the German Society of Cardiology and German Society for Clinical Research. The registry follows technical standards from Health Level Seven International (HL7) and metadata schemas promoted by WHO, with legal intersections involving the Medicinal Products Act (Arzneimittelgesetz) and data-protection frameworks under Bundesdatenschutzgesetz and the General Data Protection Regulation. Compliance mechanisms reflect editorial control, verification practices similar to those at European Medicines Agency and linkage with publication policies advocated by International Committee of Medical Journal Editors.

Accessibility and Use by Researchers and Public

The platform supports search and export features used by systematic reviewers at Cochrane and health technology assessment teams at Institute for Quality and Efficiency in Health Care (IQWiG). Public-facing summaries enable patients and advocacy groups such as German Cancer Society and Deutsche Rheuma-Liga to find recruiting trials at hospitals including Hannover Medical School and research centers like DZNE. Data accessibility complements repositories such as Zenodo and trial-report aggregation efforts by EU Trials Tracker and informs media reporting from outlets like Frankfurter Allgemeine Zeitung. Interoperability with identifiers used by PubMed, ORCID, and CrossRef supports linkage to publications and investigator profiles.

Impact, Criticism, and Notable Trials

The registry contributed to improved visibility for trials including investigator-initiated studies at University Medical Center Mainz and multicenter trials coordinated with networks like German Cancer Consortium (DKTK). Critics have cited issues similar to those raised about other registries—timeliness of updates, completeness of results reporting, and harmonization with multinational registers—echoing critiques in analyses by Transparency International-type advocates and investigative reporting by NDR. Notable registered studies span oncology, cardiology, and infectious disease projects involving collaborators such as Charité, German Centre for Infection Research (DZIF), and industry partners like Pfizer. Ongoing reforms target stricter enforcement of registration and results disclosure in line with recommendations from WHO and legal obligations under EU Clinical Trials Regulation.

Category:Clinical trial registries Category:Medicine in Germany